ArticleFrontiers in endocrinology2019
PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer.
Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- Osteocalcin Ameliorates CUMS-Induced Depressive-Like Behaviors by Reducing Mitochondrial Damage in Hippocampal Neurons.CNS neuroscience & therapeutics · 2025Article
- Mechanistic Aspects of Inflammation and Oxidative Stress and Their Association With Thyroid Cancer Risk.Cancer medicine · 2025Review
- Exercise activates AMPK in mouse and human pancreatic islets to decrease senescence.Nature metabolism · 2024Article
- LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.Cell communication and signaling : CCS · 2024Review
- Regulation of the intestinal NaAmerican journal of physiology. Cell physiology · 2024Article
- Carney Complex and Its Association With Thyroid Cancer, Molecular Pathway, and Treatment.Cureus · 2023Review
- Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.Cancers · 2023Article
- The role of liver kinase B1 in tumor progression through regulation of lipid metabolism.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Genetic susceptibility to hereditary non-medullary thyroid cancer.Hereditary cancer in clinical practice · 2022Review
- Emerging Role of cAMP/AMPK Signaling.Cells · 2022Review
- Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms.Frontiers in endocrinology · 2022Article
- Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway.Frontiers in pharmacology · 2022Article
- Activation of the adipocyte CREB/CRTC pathway in obesity.Communications biology · 2021Article
- Review
- Review
- Overcoming resistance to BRAFNPJ precision oncology · 2021Article
- Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.Genes · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Thyroid cancer affects about one percent of the population, and has seen rising incidence in recent years. Follicular thyroid cancer (FTC) comprises 10-15% of all thyroid cancers. Although FTC is often localized, it can behave aggressively with hematogenous metastasis, leading to an increased risk of cancer death. We previously described a mouse model for FTC caused by tissue-specific ablation of the Protein Kinase A (PKA) regulatory subunit
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.